Article
Value of IFNL3 genetic polymorphism in the prediction of HCV treatment response to direct-acting antiviral drugs versus interferon therapy.
Expert review of anti-infective therapy - 1 Sept 2020
Ghanem Samar E, Elsabaawy Maha, Shebl Nashwa, Abdelsameea Eman, Othman Warda, El-Bassal Fathia I, Elgedawy Gamalat A, Elsabaawy Dalia M, Helal Marwa L
Abstract excerpt
Background: Despite the outstanding results of direct-acting antiviral therapies (DAAs) of Hepatitis C infection (HCV), non-responders had to be more defined. Aim: assess the outcome of DAAs in linkage with Interferon lambda 3 (IFNL3) in HCV patients. Methods: This case-control-study was conducted on 495 chronic-HCV (genotype-4a), previously treated Egyptians by either DAAs (responders 195, 120 relapsers) or...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.